Long-time treatment by low-dose N-acetyl-L-cysteine enhances proinflammatory cytokine expressions in LPS-stimulated macrophages

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Ohnishi, Tomokazu ^a   Bandow, Kenjiro ^a   Kakimoto, Kyoko ^a   Kusuyama, Joji ^a   Matsuguchi, Tetsuya ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHOPROTEIN PHOSPHATASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; PROTEIN KINASE B; PROTEIN P53; AUTACOID; INTERLEUKIN DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOPROTEIN PHOSPHATASE; REACTIVE OXYGEN METABOLITE; TOLL LIKE RECEPTOR;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVE SITE; ENZYME PHOSPHORYLATION; ENZYME SPECIFICITY; INHIBITION KINETICS; MACROPHAGE ACTIVATION; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN INDUCTION; UPREGULATION; ANIMAL; CELL LINE; DOSE RESPONSE; DRUG EFFECTS; ENZYME ACTIVATION; ENZYMOLOGY; MACROPHAGE; METABOLISM; MOUSE; PHOSPHORYLATION; TIME;

ACETYLCYSTEINE; ANIMALS; CELL LINE; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; INFLAMMATION MEDIATORS; INTERLEUKINS; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHOPROTEIN PHOSPHATASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; TIME FACTORS; TOLL-LIKE RECEPTORS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84895156633     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087229     Document Type: Article

References (58)

1. Arakaki N, Kazi JA, Kazihara T, Ohnishi T, Daikuhara Y (1998) Hepatocyte growth factor/scatter factor activates the apoptosis signaling pathway by increasing caspase-3 activity in sarcoma 180 cells. Biochem. Biophys. Res. Commun. 245: 211-215. (Pubitemid 28414272)
2. Thannickal VJ, Fanburg BL (2000) Reactive oxygen species in cell signaling. Am. J. Physiol. Lung Cell Mol. Physiol. 279: L1005-1028. (Pubitemid 32009487)
3. Kelly GS (1998) Clinical applications of N-acetylcysteine. Altern. Med. Rev. 3: 114-127.
4. Scalley RD, Conner CS (1978) Acetaminophen poisoning: a case report of the use of acetylcysteine. Am. J. Hosp. Pharm. 35: 964-967. (Pubitemid 8397784)
5. Dodd S, Dean O, Copolov DL, Malhi GS, Berk M (2008) N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin. Biol. Ther. 8: 1955-1962.
6. Ohnishi T, Bandow K, Kakimoto K, Machigashira M, Matsuyama T, et al. (2009) Oxidative stress causes alveolar bone loss in metabolic syndrome model mice with type 2 diabetes. J. Periodontal Res. 44: 43-51.
7. Smith PD, Ochsenbauer-Jambor C, Smythies LE (2005) Intestinal macrophages: unique effector cells of the innate immune system. Immunol. Rev. 206: 149-159. (Pubitemid 41105168)
8. Raetz CR, Whitfield C (2002) Lipopolysaccharide endotoxins. Annu. Rev. Biochem. 71: 635-700. (Pubitemid 34800232)
9. Kawai T, Akira S (2007) Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med 13: 460-469.
10. Brown J, Wang H, Hajishengallis GN, Martin M (2011) TLR-signaling networks: an integration of adaptor molecules, kinases, and cross-talk. J. Dent. Res. 90: 417-427.
11. Bandow K, Maeda A, Kakimoto K, Kusuyama J, Shamoto M, et al. (2010) Molecular mechanisms of the inhibitory effect of lipopolysaccharide (LPS) on osteoblast differentiation. Biochem. Biophys. Res. Commun. 402: 755-761.
12. Haas A, Goebel W (1992) Microbial strategies to prevent oxygen-dependent killing by phagocytes. Free Radic. Res. Commun. 16: 137-157.
13. Qi S, Xin Y, Guo Y, Diao Y, Kou X, et al. (2012) Ampelopsin reduces endotoxic inflammation via repressing ROS-mediated activation of PI3K/Akt/NF-kappaB signaling pathways. Int. Immunopharmacol. 12: 278-287.
14. Lin HY, Shen SC, Lin CW, Yang LY, Chen YC (2007) Baicalein inhibition of hydrogen peroxide-induced apoptosis via ROS-dependent heme oxygenase 1 gene expression. Biochim. Biophys. Acta. 1773: 1073-1086.
15. Palacio JR, Markert UR, Martinez P (2011) Anti-inflammatory properties of N-acetylcysteine on lipopolysaccharide-activated macrophages. Inflamm. Res. 60: 695-704.
16. Krifka S, Hiller KA, Spagnuolo G, Jewett A, Schmalz G, et al. (2012) The influence of glutathione on redox regulation by antioxidant proteins and apoptosis in macrophages exposed to 2-hydroxyethyl methacrylate (HEMA). Biomaterials 33: 5177-5186.
17. Hsu HY, Wen MH (2002) Lipopolysaccharide-mediated reactive oxygen species and signal transduction in the regulation of interleukin-1 gene expression. J. Biol. Chem. 277: 22131-22139.
18. Dobashi K, Aihara M, Araki T, Shimizu Y, Utsugi M, et al. (2001) Regulation of LPS induced IL-12 production by IFN-gamma and IL-4 through intracellular glutathione status in human alveolar macrophages. Clin Exp Immunol 124: 290-296. (Pubitemid 32587614)
19. Sadowska AM, Verbraecken J, Darquennes K, De Backer WA (2006) Role of N-acetylcysteine in the management of COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 1: 425-434.
20. Dean O, Giorlando F, Berk M (2011) N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J. Psychiatry Neurosci. 36: 78-86.
21. Spapen HD, Diltoer MW, Nguyen DN, Hendrickx I, Huyghens LP (2005) Effects of N-acetylcysteine on microalbuminuria and organ failure in acute severe sepsis: results of a pilot study. Chest 127: 1413-1419. (Pubitemid 46224308)
22. Kane LP, Shapiro VS, Stokoe D, Weiss A (1999) Induction of NF-kappaB by the Akt/PKB kinase. Curr Biol 9: 601-604.
23. Gustin JA, Korgaonkar CK, Pincheira R, Li Q, Donner DB (2006) Akt regulates basal and induced processing of NF-kappaB2 (p100) to p52. J Biol Chem 281: 16473-16481.
24. Cahill CM, Rogers JT (2008) Interleukin (IL) 1beta induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT/IkappaB kinase alpha pathway targeting activator protein-1. J. Biol. Chem. 283: 25900-25912.
25. Matsuguchi T, Musikacharoen T, Johnson TR, Kraft AS, Yoshikai Y (2001) A novel mitogen-activated protein kinase phosphatase is an important negative regulator of lipopolysaccharide-mediated c-Jun N-terminal kinase activation in mouse macrophage cell lines. Mol. Cell. Biol. 21: 6999-7009. (Pubitemid 32911259)
26. Matsuguchi T, Chiba N, Bandow K, Kakimoto K, Masuda A, et al. (2009) JNK activity is essential for Atf4 expression and late-stage osteoblast differentiation. J. Bone Miner. Res. 24: 398-410.
27. Ohnishi T, Okamoto A, Kakimoto K, Bandow K, Chiba N, et al. (2010) Involvement of Cot/Tp12 in bone loss during periodontitis. J. Dent. Res. 89: 192-197.
28. Scherle PA, Jones EA, Favata MF, Daulerio AJ, Covington MB, et al. (1998) Inhibition of MAP kinase kinase prevents cytokine and prostaglandin E2 production in lipopolysaccharide-stimulated monocytes. J. Immunol. 161: 5681-5686. (Pubitemid 28519136)
29. Kang JS, Yoon YD, Lee KH, Park SK, Kim HM (2004) Costunolide inhibits interleukin-1beta expression by down-regulation of AP-1 and MAPK activity in LPS-stimulated RAW 264.7 cells. Biochem. Biophys. Res. Commun. 313: 171-177. (Pubitemid 37524040)
30. Perez RL, Ritzenthaler JD, Roman J (1999) Transcriptional regulation of the interleukin-1beta promoter via fibrinogen engagement of the CD18 integrin receptor. Am. J. Respir. Cell Mol. Biol. 20: 1059-1066. (Pubitemid 129540865)
31. Patterson KI, Brummer T, O'Brien PM, Daly RJ (2009) Dual-specificity phosphatases: critical regulators with diverse cellular targets. Biochem. J. 418: 475-489.
32. Lang R, Hammer M, Mages J (2006) DUSP meet immunology: dual specificity MAPK phosphatases in control of the inflammatory response. J. Immunol. 177: 7497-7504. (Pubitemid 44846262)
33. Traore K, Sharma R, Thimmulappa RK, Watson WH, Biswal S, et al. (2008) Redox-regulation of Erk1/2-directed phosphatase by reactive oxygen species: role in signaling TPA-induced growth arrest in ML-1 cells. J. Cell. Physiol. 216: 276-285. (Pubitemid 351813119)
34. Liao Y, Hung MC (2010) Physiological regulation of Akt activity and stability. Am. J. Transl. Res. 2: 19-42.
35. Zheng SJ, Lamhamedi-Cherradi SE, Wang P, Xu L, Chen YH (2005) Tumor suppressor p53 inhibits autoimmune inflammation and macrophage function. Diabetes 54: 1423-1428. (Pubitemid 40586673)
36. Alam K, Ghousunnissa S, Nair S, Valluri VL, Mukhopadhyay S (2010) Glutathione-redox balance regulates c-rel-driven IL-12 production in macrophages: possible implications in antituberculosis immunotherapy. J Immunol 184: 2918-2929.
37. Zhang Q, Claret FX (2012) Phosphatases: the new brakes for cancer development? Enzyme Res. 2012: 659649.
38. Lee CH, Chen JC, Hsiang CY, Wu SL, Wu HC, et al. (2007) Berberine suppresses inflammatory agents-induced interleukin-1beta and tumor necrosis factor-alpha productions via the inhibition of IkappaB degradation in human lung cells. Pharmacol. Res. 56: 193-201. (Pubitemid 47321202)
39. Vurusaner B, Poli G, Basaga H (2012) Tumor suppressor genes and ROS: complex networks of interactions. Free Radic Biol Med 52: 7-18.
40. Santhanam U, Ray A, Sehgal PB (1991) Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc. Natl. Acad. Sci. U S A 88: 7605-7609. (Pubitemid 21915202)
41. Zhang S, Zheng M, Kibe R, Huang Y, Marrero L, et al. (2011) Trp53 negatively regulates autoimmunity via the STAT3-Th17 axis. FASEB J. 25: 2387-2398.
42. Schneider-Merck T, Pohnke Y, Kempf R, Christian M, Brosens JJ, et al. (2006) Physical interaction and mutual transrepression between CCAAT/enhancer-binding protein beta and the p53 tumor suppressor. J Biol Chem 281: 269-278. (Pubitemid 43671186)
43. Tu SP, Chi AL, Ai W, Takaishi S, Dubeykovskaya Z, et al. (2009) p53 inhibition of AP1-dependent TFF2 expression induces apoptosis and inhibits cell migration in gastric cancer cells. Am J Physiol Gastrointest Liver Physiol 297: G385-396.
44. Wu GS (2004) The functional interactions between the p53 and MAPK signaling pathways. Cancer Biol. Ther. 3: 156-161.
45. Minden A, Lin A, McMahon M, Lange-Carter C, Derijard B, et al. (1994) Differential activation of ERK and JNK mitogen-activated protein kinases by Raf-1 and MEKK. Science 266: 1719-1723.
46. Leotoing L, Manin M, Monte D, Baron S, Communal Y, et al. (2007) Crosstalk between androgen receptor and epidermal growth factor receptor-signalling pathways: a molecular switch for epithelial cell differentiation. J. Mol. Endocrinol. 39: 151-162. (Pubitemid 47337873)
47. Matteucci E, Modora S, Simone M, Desiderio MA (2003) Hepatocyte growth factor induces apoptosis through the extrinsic pathway in hepatoma cells: favouring role of hypoxia-inducible factor-1 deficiency. Oncogene 22: 4062-4073. (Pubitemid 36819646)
48. Lee SY, Shin SJ, Kim HS (2013) ERK1/2 activation mediated by the nutlin-3-induced mitochondrial translocation of p53. Int. J. Oncol. 42: 1027-1035.
49. Parasassi T, Brunelli R, Costa G, De Spirito M, Krasnowska E, et al. (2010) Thiol redox transitions in cell signaling: a lesson from N-acetylcysteine. Scientific World Journal 10: 1192-1202.
50. Hayakawa M, Miyashita H, Sakamoto I, Kitagawa M, Tanaka H, et al. (2003) Evidence that reactive oxygen species do not mediate NF-kappaB activation. EMBO J. 22: 3356-3366. (Pubitemid 36834865)
51. Tuttle S, Horan AM, Koch CJ, Held K, Manevich Y, et al. (1998) Radiation-sensitive tyrosine phosphorylation of cellular proteins: sensitive to changes in GSH content induced by pretreatment with N-acetyl-L-cysteine or L-buthionine-S,R-sulfoximine. Int. J. Radiat. Oncol. Biol. Phys. 42: 833-838. (Pubitemid 28559427)
52. Liu M, Pelling JC, Ju J, Chu E, Brash DE (1998) Antioxidant action via p53-mediated apoptosis. Cancer Res. 58: 1723-1729. (Pubitemid 28215100)
53. Grandjean EM, Berthet P, Ruffmann R, Leuenberger P (2000) Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 22: 209-221. (Pubitemid 30152100)
54. Rasmussen JB, Glennow C (1988) Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis. Eur Respir J 1: 351-355.
55. Jackson IM, Barnes J, Cooksey P (1984) Efficacy and tolerability of oral acetylcysteine (Fabrol) in chronic bronchitis: a double-blind placebo controlled study. J Int Med Res 12: 198-206. (Pubitemid 14148225)
56. Grant PR, Black A, Garcia N, Prieto J,Garson JA (2000) Combination therapy with interferon-alpha plus N-acetyl cysteine for chronic hepatitis C: a placebo controlled double-blind multicentre study. J Med Virol 61: 439-442. (Pubitemid 30450684)
57. Spada C, Treitinger A, Reis M, Masokawa IY, Verdi JC, et al. (2002) The effect of N-acetylcysteine supplementation upon viral load, CD4, CD8, total lymphocyte count and hematocrit in individuals undergoing antiretroviral treatment. Clin Chem Lab Med 40: 452-455. (Pubitemid 34693083)
58. Nakamura H, Masutani H, Yodoi J (2002) Redox imbalance and its control in HIV infection. Antioxid Redox Signal 4: 455-464. (Pubitemid 34753384)